


IMPROVES TELEMEDICINE PROGRAMS



optomap color rg

optomap has been implemented in many large telehealth programs used in tens of thousands of subjects. The addition of optomap has demonstrated increased disease detection rates and shown significant efficiency benefits.¹

- **optomap** may be an essential element to an ocular telehealth screening program.¹⁻⁸ Ease of capture and review allow for point of care evaluation thereby reducing reading center burden.¹⁻¹⁰
- Ocular telemedicine programs that include **optomap** ultra-widefield imaging have a nearly double detection rate of diabetic retinopathy (DR) and more effectively identify patients at high risk for progression.^{1,3}
- Implementing **optomap** reduces ungradable rates by 81% down to 2%, image capture time by 50% and image evaluation time by 28%, due to the ability to easily image through small pupils and media opacity.^{1,3,6}
- OptosAdvance™ allows for remote image review and efficient review of multi-layer images (color, red and green channels).¹
- **optomap** has demonstrated that 20% of subjects have non-diabetic ocular findings identified on retinal imaging, regardless of the severity of their retinopathy.⁹

“It has become the default imaging system...because it has greater clinical accuracy, requires fewer images, incorporates automatic image acquisition, and lowers the proportion of poor images from which readers cannot make a diagnosis of DR/DME severity level.”

— Telemedicine and e-Health, 2020

CLINICAL SUMMARY



OptosAdvance screen showing multimodality comprehensive patient review of a case of nonproliferative DR with PPL.

- Diabetic retinopathy was identified 17% more frequently after **optomap** was implemented and predominantly peripheral lesions (PPL) may have suggested a more severe diabetic retinopathy level in up to 13% of patients, consistent with other published studies.^{1,2,4,5,6,7}
- Presence of PPL on **optomap** have a nearly 5-fold increased risk of diabetic retinopathy progression.¹²
- Adding **optomap** to Internal Medicine DR departments and community health centers increases the screening compliance rate by up to 19% and in underserved, urban communities with 28% of patients at one site not previously seen in the ophthalmology department.^{11,13}
- In one study, **optomap** implemented in a telemedicine model for DR screening, captured additional peripheral findings in 51% of patients.¹¹
- Optos provides a comprehensive image management solution called OptosAdvance which enables clinicians to review, refer, and archive images from many eye care diagnostic devices.
- Referrals for further investigation or treatment can be quickly and securely sent through OptosAdvance because of the browser design. Live consultation with colleagues via online meetings invoked from within OptosAdvance supports collaboration between colleagues at different locations about shared patients.

References:

1. Silva, P. S. et al. (2014). Potential efficiency benefits of nonmydriatic ultrawide field retinal imaging in an ocular telehealth diabetic retinopathy program. *Diabetes care*, 37(1), 50–55. <https://doi.org/10.2337/dc13-1292>
2. Silva, P. S. et al. (2015). Real-Time Ultrawide Field Image Evaluation of Retinopathy in a Diabetes Telemedicine Program. *Diabetes care*, 38(9), 1643–1649. <https://doi.org/10.2337/dc15-0161>
3. Silva, P. S. et al. (2016). Identification of Diabetic Retinopathy and Ungradable Image Rate with Ultrawide Field Imaging in a National Teleophthalmology Program. *Ophthalmology*, 123(6), 1360–1367. <https://doi.org/10.1016/j.ophtha.2016.01.043>
4. Shachar Tauber et al.; Implementation Of An Ocular Telehealth Program Using Ultrawidefield Images To Increase Diabetic Eye Screening. *Invest. Ophthalmol. Vis. Sci.* 2012;53(14):2072.
5. Hussain, N. et al. (2017). Telemedicine for diabetic retinopathy screening using an ultra-widefield fundus camera. *Clinical ophthalmology* (Auckland, N.Z.), 11, 1477–1482. <https://doi.org/10.2147/OPTH.S135287>
6. Silva, P. S. et al. (2012). Nonmydriatic ultrawide field retinal imaging compared with dilated standard 7-field 35-mm photography and retinal specialist examination for evaluation of diabetic retinopathy. *American journal of ophthalmology*, 154(3), 549–559.e2. <https://doi.org/10.1016/j.ajo.2012.03.019>
7. Silva, P. S. et al. (2013). Peripheral lesions identified by mydriatic ultrawide field imaging: distribution and potential impact on diabetic retinopathy severity. *Ophthalmology*, 120(12), 2587–2595. <https://doi.org/10.1016/j.ophtha.2013.05.004>
8. Talks, S. J. et al. (2015). New vessels detected on wide-field imaging compared to two-field and seven-field imaging: implications for diabetic retinopathy screening image analysis. *The British journal of ophthalmology*, 99(12), 1606–1609. <https://doi.org/10.1136/bjophthalmol-2015-306719>
9. Silva, P. S. et al. (2016). Comparison of Nondiabetic Retinal Findings Identified With Nonmydriatic Fundus Photography vs Ultrawide Field Imaging in an Ocular Telehealth Program. *JAMA ophthalmology*, 134(3), 330–334. <https://doi.org/10.1001/jamaophthalmol.2015.5605>
10. Fonda, S. J. et al. (2020). The Indian Health Service Primary Care-Based Teleophthalmology Program for Diabetic Eye Disease Surveillance and Management. *Telemedicine journal and e-health : the official journal of the American Telemedicine Association*, 26(12), 1466–1474. <https://doi.org/10.1089/tmj.2019.0281>
11. Michelle Nguyen et al.; The Utility of Ultra-widefield Retinal Imaging with Telemedicine for Diabetic Retinopathy Screening. *Invest. Ophthalmol. Vis. Sci.* 2020;61(7):4848.
12. Silva, P. S. et al. (2015). Peripheral Lesions Identified on Ultrawide Field Imaging Predict Increased Risk of Diabetic Retinopathy Progression over 4 Years. *Ophthalmology*, 122(5), 949–956. <https://doi.org/10.1016/j.ophtha.2015.01.008>
13. Ha, S. K. et al. (2025). Impact of teleretinal screening program on diabetic retinopathy screening compliance rates in community health centers: a quasi-experimental study. *BMC health services research*, 25(1), 318. <https://doi.org/10.1186/s12913-025-12472-8>

optomap is available on Daytona, California, MonacoPro and Silverstone RGB.



Optos UK/Europe
+44 (0)1383 843350
ics@optos.com

Optos North America
800 854 3039
usinfo@optos.com

Optos DACH
DE: 0800 72 36 805
AT: 0800 24 48 86
CH: 0800 55 87 39
ics@optos.com

Optos Australia
+61 8 8444 6500
auinfo@optos.com

